Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewAgingImmunologyInfectious disease Open Access | 10.1172/jci.insight.195618

Age-related differences in immune responses to inactivated influenza and adjuvanted recombinant herpes zoster vaccines

Gizem Kilic,1 Esther J.M. Taks,1 Leonie S. Helder,1 Elisabeth A. Dulfer,1 Büsra Geckin,1 Liesbeth van Emst,1 Heidi Lemmers,1 Stefano Berrè,2 Adhidev Biswas,2 Mumin Ozturk,4 Yutaka Negishi,4 Wivine Burny,2 Sofia Maria Buonocore,2 Jaap ten Oever,1 Musa M. Mhlanga,4 and Mihai G. Netea1

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Kilic, G. in: PubMed | Google Scholar |

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Taks, E. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Helder, L. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Dulfer, E. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Geckin, B. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by van Emst, L. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Lemmers, H. in: PubMed | Google Scholar |

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Berrè, S. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Biswas, A. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Ozturk, M. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Negishi, Y. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Burny, W. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Buonocore, S. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by ten Oever, J. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Mhlanga, M. in: PubMed | Google Scholar

1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands

2GSK, Rixensart, Belgium

3GSK, Bengaluru, India

4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands

Find articles by Netea, M. in: PubMed | Google Scholar

Published June 2, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.195618.
Copyright © 2026, Kilic et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published June 2, 2026 - Version history
View PDF
Abstract

Immunosenescence, the biological aging of the immune system, leads to dysregulated immune responses, increasing susceptibility to infections and reducing vaccine efficacy in older adults, as seen with flu vaccines. In contrast, the AS01-adjuvanted recombinant herpes zoster vaccine (RZV) maintains high and sustained efficacy, offering 82% protection against herpes zoster at 11-years post-vaccination, in individuals over 50. To identify factors impacting age-dependent vaccine efficacy, we conducted a randomized, partially placebo-controlled clinical study. Young adults (18-35 years, n=84) were randomized 3:3:1:1 to receive either RZV, an inactivated quadrivalent seasonal influenza vaccine (IIV4), placebo for RZV or placebo for IIV4, while older adults (≥60, n=63) were randomized 1:1 to receive RZV or IIV4. RZV elicited robust antibody production, antigen-specific polyfunctional CD4+ T cell responses and IFN-γ from PBMCs in both age groups, while IIV4 increased antibody responses, but induced fewer antigen-specific CD4+ T cells and no elevation of IFN-γ from PBMCs. Interestingly, RZV reduced systemic inflammation in older adults, particularly after the second injection. Baseline inflammation negatively correlated with antibody production and IFN-γ response, especially after RZV. Our findings suggest that RZV may help overcome immunosenescence by enhancing cellular responses and potentially decreasing systemic inflammation, deserving further investigation into the underlying molecular mechanisms.

Supplemental material

View

Version history
  • Version 1 (June 2, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts